SCHEMBL5154770

SCHEMBL5154770

COc1ccc(P(Br)Br)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA14 Q9ULX7 1/20 0.56
CYP1A1 P04798 7/20 0.48
CYP1A2 P05177 7/20 0.48
CYP1B1 Q16678 7/20 0.48
ALDH1A1 P00352 5/20 0.48
CYP3A4 P08684 2/20 0.48
MAPT P10636 3/20 0.47
HPGD P15428 2/20 0.47
RAD52 P43351 1/20 0.47
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
CYP2E1 P05181 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2A6 P11509 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17377389 0.88 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL2884396 0.83 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL8029752 0.83 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL29509911 0.83 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL31240957 0.83 CA12 (0.60) CA12CA1CA2CA7CA9
SCHEMBL667942 0.83 CA12 (0.60) CA12CA1CA2CA7CA9
SCHEMBL9838572 0.81 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL18855065 0.81 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL8722412 0.78 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL1038081 0.78 CYP1A2 (0.42) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1235764-B1 CATALYSIS USING PHOSPHINE OXIDE COMPOUNDS DU PONT (US) 2007-01-10 EP disclosed
EP-1294657-B1 CATALYSIS USING PHOSPHINE OXIDE AND SULFOXIDE COMPOUNDS DU PONT (US) 2005-01-19 EP disclosed
US-6762330-B2 MAKING BIARYLS BY REACTING A GRIGNARD REAGENT AND AN ARYL HALIDE IN THE PRESENCE OF A TRANSITION METAL COMPLEX WITH A PHOSPHINE OXIDE OR PHOSPHINE SULFOXIDE (HP(=S) TYPE) AS CATALYST E. I. DU PONT DE NEMOURS AND COMPANY 2004-07-13 US disclosed
US-6716984-B2 CONTACTING PHOSPHINE COMPOUND OFTHE FORMULA XPR1R2, WHEREIN X IS A HALOGEN, WITH THE SOLID SUPPORT, RESULTING IN THE P IN THE PHOSPHINE ATTACHED INDIRECTLY OR DIRECTLY TO SOLID SUPPORT VIA A COVALENT BONDS, AND REPLACING R1 OR R2 GROUPS E. I. DU PONT DE NEMOURS AND COMPANY 2004-04-06 US disclosed
EP-1294657-A2 CATALYSIS USING PHOSPHINE OXIDE AND SULFOXIDE COMPOUNDS E. I. du Pont de Nemours and Company (US) 2003-03-26 EP disclosed
EP-1274744-A2 POLYMER-SUPPORTED SYNTHESIS OF HETEROATOM BIDENTATE LIGANDS FOR CATALYSIS E.I. DUPONT DE NEMOURS AND COMPANY, Legal Patent Records Center (US) 2003-01-15 EP disclosed
US-20020137974-A1 Catalysis using phosphine oxide and sulfoxide compounds DUPONT POLYMERS, INC. 2002-09-26 US disclosed
EP-1235764-A1 CATALYSIS USING PHOSPHINE OXIDE COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2002-09-04 EP disclosed
US-20020077479-A1 Polymer-supported synthesis of heteroatom bidentate ligands for catalysis E. I. DU PONT DE NEMOURS AND COMPANY 2002-06-20 US disclosed
WO-2002000574-A2 CATALYSIS USING PHOSPHINE OXIDE AND SULFOXIDE COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2002-01-03 WO disclosed
WO-2001079213-A2 POLYMER-SUPPORTED SYNTHESIS OF HETEROATOM BIDENTATE LIGANDS FOR CATALYSIS E.I. DUPONT DE NEMOURS AND COMPANY (US) 2001-10-25 WO disclosed
US-6291722-B1 CONTACTING GRIGNARD REAGENT OF FORMULA R.SUP.7--MGX WITH AN ARYL COMPOUND OF THE FORMULA R.SUP.1--X IN THE PRESENCE OF A CATALYTIC AMOUNT OF COORDINATION COMPRISING TRASITION METAL COMPLEXED TO PHOSPHINE OXIDE TO PREPARE BISARYL COMPOUND E. I. DU PONT DE NEMOURS AND COMPANY 2001-09-18 US disclosed
WO-2001040147-A1 CATALYSIS USING PHOSPHINE OXIDE COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2001-06-07 WO disclosed
US-6124462-A PREPARING ARYLAMINE AND BIARYLS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2000-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137974-A1 Catalysis using phosphine oxide and sulfoxide compounds TST, GSS, ARSA CA12 3635/4885CA1 3990/4885CA2 4079/4885
US-20020077479-A1 Polymer-supported synthesis of heteroatom bidentate ligands for catalysis PARG, PCNA, PARN CA12 1077/4885CA1 1663/4885CA2 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.